Fosun Pharmaceutical (600196.SH): FXS887 tablets approved for clinical trials for advanced malignant solid tumors

Zhitongcaijing · 3d ago

Zhitong Finance App News, Fosun Pharmaceutical (600196.SH) issued an announcement. Recently, Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. (hereinafter referred to as “Fosun Pharmaceutical Industry”), the company's holding subsidiary, received approval from the State Drug Administration to agree to use FXS887 tablets (project code and “FXS0887”) to conduct clinical trials for advanced malignant solid tumors. Fosun Pharmaceutical Industry plans to launch Phase I clinical trials of FXS0887 in China when conditions are met.

FXS0887 is an innovative oral small molecule drug independently developed by the Group (that is, the company and its holding subsidiaries/units, the same below). It is intended to be used to treat advanced malignant solid tumors. FXS0887 specifically inhibits ATR (Ataxia Telangiectasia and RAD3-related) kinase activity and inhibits malignant proliferation of tumor cells by interfering with cell cycle regulation and DNA damage repair related pathways. Pre-clinical studies to date have shown that FXS0887 has shown good anti-tumor activity in various tumor models, less risk of off-target, and good safety.